Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Preliminary Results of the METROS Trial

被引：5

作者：

Landi, Lorenza ^{[1
]}

Chella, Antonio ^{[2
]}

Chiari, Rita ^{[3
]}

Tiseo, Marcello ^{[4
]}

Buosi, Roberta ^{[5
]}

Dazzi, Claudio ^{[6
]}

Gridelli, Cesare ^{[7
]}

Barbieri, Fausto ^{[8
]}

Delmonte, Angelo ^{[9
]}

Ali, Greta ^{[10
]}

Fontanini, Gabriella ^{[10
]}

Crino, Lucio ^{[3
]}

Cappuzzo, Frederico ^{[6
]}

机构：

[1] Ist Toscano Tumori, Oncol, Livorno, Italy

[2] Pneumol Univ, Dipartimento Cardiotorac & Vasc, Osped Cisanello, Pisa, Italy

[3] Santa Maria Della Misericordia Hosp, Med Oncol, Perugia, Italy

[4] Univ Hosp Parma, Med Oncol, Parma, Italy

[5] AOU Maggiore Della Carita, Novara, Italy

[6] Ausl Romagna, Ravenna, Italy

[7] Azienda Osped SG Moscati, Avellino, Italy

[8] Univ Hosp Policlin Modena, Oncol Unit, Modena, Italy

[9] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy

[10] Univ Pisa, Dipartimento Patol Mol & Area Crit, Programma Patol Pleuro Polmonare, Pisa, Italy

来源：

关键词：

MET; crizotinib; NSCLC; METROS;

D O I：

10.1016/j.jtho.2016.11.429

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.06

引用

页码：S380 / S381

页数：2